ERBB2 and neoplasm: To verify whether the HER2-dual targeting exosomes (293-miR-XS-HER2) have improved antitumor efficacy compared with HER2 single targeting miRNA only (293-miR-XS) and non-targeting exosomes (293) in vivo by intravenous administration, HER2-positive tumor cells SK-OV-3 were transplanted into BALB/c nude mice.